A screening device for peripheral neuropathy
Our technology, Neurosense, which is short for Neuropathy Sense, is developed with the aim of reducing the cost and increasing the sensitivity of peripheral neuropathy screening to meet the needs of Primary Care screening. To achieve this goal, we have focused on minimizing the mechanical parts in order to reduce the cost, error margins, risks, and vulnerabilities associated with these components. We have also paid special attention to the concept of reusability, where we developed a technology that outsources many of its mechanical and electronic components to commonly available smartphones. Our technology, is therefore, comprised of a peripheral probe, a smartphone application, and an artificially intelligent (AI) agent. The end-user product is amazingly simple both in terms of hardware and operations. This simplicity will not only increase the user-friendliness of our technology but also will reduce its cost and increase its accuracy, reliability, and durability.
Neuroense has recently won the University of Utah's Bench to Bedside (B2B) 2019-20 Best in Medicine Award. B2B is a trans-disciplinary experiential educational program at the University of Utah's Center for Medical Innovation that teaches the impact and the power diversity of thought can bring to the innovation process.
Neurosense has been accepted to the Autumn 2020 Polsky Center I-Corps Program. The Polsky Center I-Corps program is aimed to empower University of Chicago's scientists, researchers, and students to test the commercial potential of their research and ideas. I-Corps is supported by a grant from the National Science Foundation (NSF), run by the University of Chicago's Polsky Center for Entrepreneurship and Innovation
The Lassonde Entrepreneur Institute of the University of Utah has added Neurosense in its list of Lassonde New Venture Development Program. The program consists of an interdisciplinary team to develop companies with faculty inventors, industry professionals, and entrepreneurs.
Provisional Patent 2
Neurosense has filed its second provisional patent application with the United States Patent and Trademark Office to include the artificial intelligence portion of our neuropathy device. The device will use artificial intelligence to diagnose neuropathy. Over time, It will learn the medical diagnoses offered by neurologists. Neurosense is expected to soon have higher diagnostic accuracy than human medical experts.
Provisional Patent 1
Neurosense filed its first provisional patent application with the United States Patent and Trademark Office. Neurosense team has developed an instrument that can be used for the screening and severity examination of neuropathy. The device will significantly bring down the cost of neuropathy accurate screening. The invention is expected to ultimately impact more than 50 million Americans who are at increased risk of neuropathy.
Neurosense v2.0 will be released soon. The new version will have increased convenience which now using wireless technology to connect the peripheral device to the smartphone. The new wireless version will also have larger and stronger range which can be used for severity examination of neuropathy apart from the main objective of Neurosense which is neuropathy screen in primary care.